IMPOWER110

NCT02409342 📎

Regimen

Experimental
atezolizumab
Control
platinum doublet

Population

PD-L1-high advanced NSCLC 1L

Key finding

TC3/IC3: mOS 20.2 vs 13.1 mo, HR 0.59 (0.40-0.89); atezolizumab 1L PD-L1-high

Source: PMID 32997907

Timeline

  • Enrollment start: 2015-07-20 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.173)
  • CSCO NSCLC 2025 ⚠️ OCR source